Gadot Biochemical Industries, a leading global supplier of mineral-based ingredients, will spotlight its innovative magnesium and calcium ingredient solutions at the IFT FIRST Annual Event and Expo, taking place July 14–16 in Chicago. Visitors to Booth S2457 will discover how Gadot’s scientifically supported portfolio, including its Cal2Mag, addresses the growing demand for cardiovascular wellness, bone health, and clean-label product development.
Recent research continues to affirm magnesium’s critical role in cardiovascular protection. A pivotal study from the Women’s Health Initiative found that higher dietary magnesium intake significantly reduced the risk of fatal coronary heart disease in postmenopausal women, with a noted trend toward reduced sudden cardiac death1. Supporting this, pre-clinical studies demonstrate that oral magnesium supplementation can help prevent vascular calcification, particularly when paired with alkalising agents such as potassium citrate2.
A balanced ratio of magnesium to calcium also plays a vital role in regulating pyrophosphate (PPi), an essential inhibitor of arterial calcification. Studies show that when calcium is consumed in excess of magnesium, PPi hydrolysis increases, raising the risk of vascular mineral buildup. Maintaining an optimal Mg:Ca ratio may offer a protective effect by preserving PPi stability in the aortic wall3.
Gadot’s Cal2Mag is specifically designed to address this balance. Cal2Mag is a synergistic mineral complex that combines two parts calcium with one part magnesium, scientifically formulated to reflect the body’s ideal ratio for absorption and metabolic balance. Unlike standalone calcium or magnesium products, Cal2Mag delivers dual benefits for bone integrity and cardiovascular protection. It is highly soluble, vegan-friendly, and easily incorporated into a wide range of applications including gummies, tablets, powders, and beverages. Cal2Mag is an ideal solution for brands targeting consumers interested in bone and heart health without the digestive discomfort often associated with high-dose calcium supplementation.
In addition to Cal2Mag, Gadot will be showcasing its expanding magnesium product line at IFT FIRST, including fully reacted magnesium bisglycinate, known for high bioavailability and digestive tolerance, and buffered magnesium bisglycinate chelate, which offers enhanced stability for more complex formulations. Magnesium citrate and magnesium oxide remain valuable options for general wellness, hydration, and cost-effective fortification strategies.
Attendees of IFT FIRST are encouraged to visit Booth S2457 to engage with Gadot’s R&D team, sample formulations, and explore new ways to develop heart-healthy, consumer-friendly functional products.
References
- Mursu, J. et al. “Dietary Magnesium Intake and the Risk of Cardiovascular Disease: The Women’s Health Initiative Study.” Journal of Women’s Health, 2020. [File: Deetary Mg & Coronary effect.pdf]
- Bressendorff, I. et al. “Oral Magnesium Supplementation Prevents Vascular Calcification in Rats with Chronic Kidney Disease.” Biomedicine & Pharmacotherapy, 2019. [File: Deetary Mg & Coronary effect.pdf]
- Turgut, F. et al. “Magnesium to Calcium Ratio Modulates Aortic Wall Calcification Through Regulation of Pyrophosphate Hydrolysis.” J Mol Med, 2015. [File: MgCa Ratio.pdf]
